New Delhi, Feb 28 (PTI) BDR Pharmaceuticals on Monday said it has launched prostate cancer treatment drug Enzalutamide in 160 mg strength.

The company has introduced the medication, under the brand name BDENZA 160mg, at Rs 6,300 for a strip of seven tablets.

Also Read | EXIM Bank Recruitment 2022: Apply For 25 Management Trainee Posts at eximbankindia.in; Check Details Here.

The medicine was previously available in 40 mg and 80 mg strength for which patients had to consume two tablets a day.

The objective behind the launch of Enzalutamide 160 mg is to ensure better efficacy, minimum side effects, contain relapse cases by blocking the hormones of cancer cells providing an evolved treatment, BDR Pharmaceuticals said in a statement.

Also Read | JioGames Collaborates With OnePlus To Bring Its Games Library to OnePlus Smart TVs.

"Our focused launch of such expanded brand strength will definitely add value to Indian oncology patients as well as provide opportunity for medical physicians to comply with patient outcome and standard treatment protocol.

"This represents a firm commitment to providing access to affordable medicines for Indian cancer patients with high quality standards," BDR Pharmaceuticals Director Business Development Raheel Shah noted.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)